Special Meeting of Shareholders to Approve Plan to be Held on March 20, 2026 Special Meeting of Shareholders to Approve Plan to be Held on March 20, 2026
Bitcoin Everlight is drawing comparisons to Bitcoin's early participation phase as its public presale continues through Phase 2, with total contributions now exceeding $250,000.SAN FRANCISCO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Bitcoin Everlight confirmed that its multi-stage public presale remains active, with Phase 2 priced at $0.0010 approaching completion. The current stage of participation has prompted comparisons to Bitcoin's early network period, when engagement centered on system involvement and infrastructure contribution before widespread attention developed.Bitcoin's first years were defined by hands-on participation. Contributors interacted with the network by running nodes, testing transaction behavior, and observing system performance under real conditions. Visibility followed after those foundations were established. That pattern has resurfaced in how early-stage Bitcoin-adjacent networks are now being approached.Participation Patterns Anchored in Bitcoin's HistoryDuring Bitcoin's initial growth phase, engagement reflected curiosity about how the network functioned in practice. Participants evaluated reliability, transaction flow, and coordination across the system. Market narratives came later.Bitcoin Everlight is progressing within a similar participation environment. Current interest has centered on how the network operates, how transactions are coordinated, and how development milestones are communicated as the system evolves. These factors have shaped presale activity independently of short-term Bitcoin price movement.Development Activity and Update CadenceAlongside presale participation, Bitcoin Everlight has maintained a steady schedule of developer updates. These updates outline progress across transaction handling, node functionality, and network coordination, with releases tied to completed testing milestones.The update cadence reflects an execution-driven approach. Information is published as components advance through defined stages, providing visibility into development status without relying on market conditions to frame progress."Updates are released when technical checkpoints are reached," said Michael G. Dennehy, spokesperson for Bitcoin Everlight. "The goal is ...Full story available on Benzinga.com
It is hard to see how Internet Computer can rebuild investor confidence.
Gov. Gordon signs emergency rules to administer property tax exemption
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Marex Group plc ((‘Marex' or the ‘Group', NASDAQ:MRX), the diversified global financial services platform, today announces that it has agreed to acquire European equity derivatives market maker Webb Traders to enhance its market making capabilities.Webb Traders has offices in Amsterdam and Paris and specialises in single stock options market making for European and US mid and large cap equities. The acquisition will bring to Marex a strong, technology led team of market makers, quants and developers, as well as electronic trading capabilities. Webb Traders' trading and risk management philosophy is fully aligned with Marex's approach.The acquisition is expected to further enhance Marex's established Equity Linked Structured Products platform allowing the Group to internalise hedging, enhance profit margins and provide better pricing for clients. The deal is subject to regulatory approval and is expected to close in the second or third quarter of 2026. Ian Lowitt, Chief Executive Officer of Marex, commented: "We are excited to welcome the team from Webb Traders to Marex. They have built an incredibly talented team supported by excellent technology, which will enhance our equity derivatives capabilities. They have a prudent approach to risk and have been profitable across a range of market environments, which, combined with the ability to internalise some hedging costs, will be beneficial to Marex."Forward-Looking Statements:This press release contains ...Full story available on Benzinga.com
Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025 Cash of $17.6 Million at December 31, 2025 LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in...
VANCOUVER, BC , Feb. 6, 2026 /PRNewswire/ - Thesis Gold Inc. ("Thesis" or the "Company") (TSXV:TAU) (WKN: A3EP87) (OTCQX:THSGF) is pleased to announce the appointment of Ms. Coille van Alphen to its Board of Directors, effective immediately. Ms. van Alphen is a seasoned mining investment professional with over 15 years of experience across public equities, capital markets, and strategic investing. She currently serves as a Mining & Metals Portfolio Manager at Equinox Partners, a value-oriented investment firm with a long-term focus on resource equities and the largest institutional shareholder of Thesis. Previously, Ms. van Alphen held senior investment roles at the Canada Pension Plan Investment Board and Canaccord Genuity, where she focused on global mining and metals investments. Her appointment further strengthens the Company's Board as Thesis transitions from advanced exploration into ...Full story available on Benzinga.com
A return to top-tier form.
Jeweller Pandora has said it will switch from using silver in some of its ranges to platinum following a dramatic increase in prices. Silver has seen its price more than double over the past year, with other precious metal prices also surging. Pandora’s chief executive said its aim was not to make all jewellery platinum-plated, [...]
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a highly morbid, chronic, and disfiguring condition with no approved therapies, and the BEACON study is the first ever industry-sponsored placebo-controlled trial in the indication to read out positively.
BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for the third quarter ended December 31, 2025.